With data integrity issues increasingly dominating FDA's drug GMP warning letters, agency and industry representatives are urging pharmaceutical manufacturers to attack the problem with cultural and electronic "human factors" preventive measures.
"One of the themes I think that we see is the issue of human factors continuing with respect to data integrity," said Thomas Cosgrove, acting director of the Office of...